Michael Bukhalo, MD
Dermatology · Rolling Meadows, ILNPI 1548239734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,170 of the $88,709 with a category attached, or 67.8%. 37 manufacturers reported payments, led by Amgen at 29.1% of the total. Reporting peaked in 2019 at $46,448 and has fallen 96.1% since, to $1,809 in 2025. Among dermatology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 613 payments — averaging $144.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- Novartis$20K
- Bristol Myers Squibb$19K
- AbbVie$10K
- UCB, Inc.$3K
- LEO Pharma Inc.$2K
- plus $8K from 31 others
Across 814 payments — averaging $9544.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2.3M
- Eli Lilly$2.3M
- Janssen Research & Development, LLC$1.6M
- Takeda Pharmaceuticals U.S.A., Inc.$752K
- Acrotech Biopharma Inc.$238K
- E.r. Squibb & Sons, L.L.C.$225K
- plus $390K from 10 others
What the payments were for
- Consulting fees$12,74714%
- Speaking & faculty fees$60,17068%
- Travel & lodging$3,0343%
- Food & beverage$12,20514%
- Education$5541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 58 | $25,853 |
| Novartis | 59 | $20,219 |
| Bristol Myers Squibb | 31 | $19,401 |
| AbbVie(2 entities) | 133 | $9,828 |
| UCB, Inc. | 16 | $2,744 |
| LEO Pharma Inc. | 8 | $2,334 |
| Arcutis Biotherapeutics, Inc. | 9 | $1,148 |
| Johnson & Johnson | 40 | $1,071 |
| Almirall LLC | 2 | $814 |
| E.r. Squibb & Sons, L.L.C. | 34 | $651 |
| Lilly USA, LLC | 34 | $625 |
| Sanofi | 25 | $598 |
| Galderma Laboratories, L.p. | 36 | $521 |
| Regeneron Healthcare Solutions, Inc. | 16 | $457 |
| VYNE Pharmaceuticals Inc. | 21 | $428 |
| Mayne Pharma Commercial LLC | 16 | $402 |
| Sun Pharmaceutical Industries Inc. | 18 | $341 |
| Pfizer | 13 | $226 |
| Janssen Research & Development, LLC | 1 | $222 |
| Incyte Corporation | 6 | $142 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $100 |
| Boehringer Ingelheim | 4 | $92 |
| EPI Health, LLC | 5 | $68 |
| Smith+Nephew | 4 | $67 |
| Organon | 3 | $66 |
| Botanix SB Inc | 3 | $62 |
| Sandoz | 2 | $35 |
| Misonix Inc | 1 | $30 |
| Dermira, Inc. | 1 | $24 |
| DUSA Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Biofrontera Inc. | 1 | $19 |
| Aclaris Therapeutics, Inc. | 1 | $18 |
| LNHC, Inc | 1 | $17 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,709 in reported general payments places this provider in the 90th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 20 | $269,917 |
| Dupixent SyringeDupilumab | 17 | $91,395 |
| Dupixent PenDupilumab | 16 | $59,687 |
| OtezlaApremilast | 11 | $49,714 |
| CiclopiroxCiclopirox Olamine | 228 | $9,119 |
| Hydrocortisone | 510 | $7,787 |
| Triamcinolone Acetonide | 496 | $7,545 |
| Ketoconazole | 547 | $7,232 |
| Tacrolimus | 30 | $5,969 |
| Betamethasone Dipropionate | 111 | $3,733 |
| Fluorouracil | 34 | $2,793 |
| Clindamycin Phosphate | 73 | $2,685 |
| Metronidazole | 51 | $2,661 |
| Ammonium Lactate | 109 | $1,795 |
| Doxycycline Hyclate | 99 | $1,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,071 | $269,91720 claims |
| AmgenOtezla | $25,853 | $49,71411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 606 dermatology providers in Illinois.
Other dermatology in Rolling Meadows
- Ahmad AminNaperville$4.1M
- Raj ChovatiyaChicago$3.6M
- George LewittNorthbrook$3M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Lana SchmidtEffingham$1.3M
- Melissa AbramsVernon Hills$600K
- Carolyn JacobChicago$566K
- Walter LiszewskiChicago$414K
- Emily RubensteinLincolnshire$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.